1,514 reports of this reaction
3.2% of all MIDAZOLAM HYDROCHLORIDE reports
#3 most reported adverse reaction
HYPOTENSION is the #3 most commonly reported adverse reaction for MIDAZOLAM HYDROCHLORIDE, manufactured by Fresenius Kabi USA, LLC. There are 1,514 FDA adverse event reports linking MIDAZOLAM HYDROCHLORIDE to HYPOTENSION. This represents approximately 3.2% of all 46,685 adverse event reports for this drug.
Patients taking MIDAZOLAM HYDROCHLORIDE who experience hypotension should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPOTENSION is moderately reported among MIDAZOLAM HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to hypotension, the following adverse reactions have been reported for MIDAZOLAM HYDROCHLORIDE:
The following drugs have also been linked to hypotension in FDA adverse event reports:
HYPOTENSION has been reported as an adverse event in 1,514 FDA reports for MIDAZOLAM HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPOTENSION accounts for approximately 3.2% of all adverse event reports for MIDAZOLAM HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience hypotension while taking MIDAZOLAM HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.